Defective complement inhibitory function predisposes to renal disease

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 307-324

  Java, Anuja ^a   Atkinson, John ^a   Salmon, Jane ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

aHUS; antiphospholipid syndrome; C3 and C1q glomerulopathy; complement inhibitors; preeclampsia

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AUTOANTIBODY; COMPLEMENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; IMMUNOGLOBULIN;

ANTIPHOSPHOLIPID SYNDROME; C1Q GLOMERULOPATHY; C3 GLOMERULOPATHY; C3 NEPHROPATHY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT FACTOR H RELATED PROTEIN 5 NEPHROPATHY; COMPLEMENT LECTIN PATHWAY; DENSE DEPOSIT DISEASE; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM CELL; GENE DELETION; GENE MUTATION; GENETICS; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOTE; HUMAN; IMMUNE COMPLEX DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PLASMAPHERESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; REPERFUSION INJURY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY TRACT DISEASE;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DNA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY DISEASES;

EID: 84873051293     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-072211-110606     Document Type: Review

References (58)

1. Markiewski MM, Nilsson B, Ekdahl KN, et al. 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28:184-92
2. PickeringMC, Cook HT. 2008. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin. Exp. Immunol. 151:210-30
3. Richards A, Kavanagh D, Atkinson JP. 2007. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv. Immunol. 96:141-77
4. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-TrascasaM, et al. 2009. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations ofCFHR1 associated with atypical hemolytic uremic syndrome. Blood 114:4261-71
5. Atkinson JP, Goodship TH. 2007. Complement factor H and the hemolytic uremic syndrome. J. Exp. Med. 204:1245-48
6. Dragon-Durey MA, Blanc C, Garnier A, et al. 2010. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin. Thromb. Hemost. 36:633-40
7. Pechtl IC, Kavanagh D, McIntosh N, et al. 2011. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J. Biol. Chem. 286:11082-90
8. Zipfel PF, Skerka C, Caprioli J, et al. 2001. Complement factor H and hemolytic uremic syndrome. Int. Immunopharmacol. 1:461-68
9. KavanaghD, Goodship TH. 2011. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematol. Am. Soc. Hematol. Educ. Program. 2011:15-20
10. Kavanagh D, Richards A, Atkinson J. 2008. Complement regulatory genes and hemolytic uremic syndromes. Annu. Rev. Med. 59:293-309 3, 9-11.
11. Loirat C, Fremeaux-Bacchi V. 2011. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 6:60
12. Delvaeye M, Noris M, DeVriese A, et al. 2009. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361:345-57
13. Hodgkins KS, Bobrowski AE, Lane JC, et al. 2012. Clinical grand rounds: atypical hemolytic uremic syndrome. Am. J. Nephrol. 35:394-400
14. Richards A, Kavanagh D. 2009. Pathogenesis of thrombotic microangiopathy: insights from animal models. Nephron. Exp. Nephrol. 113:e97-103
15. Salmon JE, Heuser C, Triebwasser M, et al. 2011. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLOS Med. 8:e1001013
16. Noris M, Remuzzi G. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361:1676-87
17. Rodriguez de Cordoba S. 2010. aHUS: a disorder with many risk factors. Blood 115:158-60
18. Abarrategui-Garrido C, MelgosaM, Pena-Carrion A, et al. 2008. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am. J. Kidney Dis. 52:171-80
19. Smith RJ, Harris CL, Pickering MC. 2011. Dense deposit disease. Mol. Immunol. 48:1604-10
20. Sethi S, Fervenza FC. 2012. Membranoproliferative glomerulonephritis-a new look at an old entity. N. Engl. J. Med. 366:1119-31
21. Benz K, Amann K. 2009. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS)/thrombocytic thrombopenic purpura (TTP). Thromb. Haemost. 101:265-70
22. Licht C, Fremeaux-BacchiV. 2009. Hereditary and acquired complement dysregulation inmembranoproliferative glomerulonephritis. Thromb. Haemost. 101:271-78
23. Bomback AS, Smith RJ, Barile GR, et al. 2012. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 7:748-56
24. Servais A, Fremeaux-Bacchi V, Lequintrec M, et al. 2007. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 44:193-99
25. Gale DP, de Jorge EG, Cook HT, et al. 2010. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376:794-801
26. Jennette JC, Hipp CG. 1985. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am. J. Kidney Dis. 6:103-10
27. Vizjak A, Ferluga D, Rozic M, et al. 2008. Pathology, clinical presentations, and outcomes of C1q nephropathy. J. Am. Soc. Nephrol. 19:2237-44
28. Miyakis S, Lockshin MD, Atsumi T, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:295-306
29. Tektonidou MG, Sotsiou F, Nakopoulou L, et al. 2004. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 50:2569-79
30. Cervera R, Tektonidou MG, Espinosa G, et al. 2011. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APSManifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 20:165-73
31. Cervera R, Asherson RA, Font J. 2006. Catastrophic antiphospholipid syndrome. Rheum. Dis. Clin. North Am. 32:575-90
32. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. 2005. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 52:2120-24
33. Willis R, Harris EN, Pierangeli SS. 2012. Pathogenesis of the antiphospholipid syndrome. Semin. Thromb. Hemost. 38:305-21
34. Shapira I, Andrade D, Allen SL, et al. 2012. Induction of durable remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 64:2719-23
35. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. 2011. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am. J. Transplant. 11:2523-27
36. Lonze BE, Singer AL, Montgomery RA. 2010. Eculizumab and renal transplantation in a patient with CAPS. N. Engl. J. Med. 362:1744-45
37. Girardi G, Berman J, Redecha P, et al. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112:1644-54
38. Shamonki JM, Salmon JE, Hyjek E, et al. 2007. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 196:167 e1-5
39. Breen KA, Seed P, Parmar K, et al. 2012. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb. Haemost. 107:423-29
40. Ilekis JV, Reddy UM, Roberts JM. 2007. Preeclampsia-a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod. Sci. 14:508-23
41. Roberts JM, Gammill HS. 2005. Preeclampsia: recent insights. Hypertension 46:1243-49
42. Young BC, Levine RJ, Karumanchi SA. 2010. Pathogenesis of preeclampsia. Annu. Rev. Pathol.Mech. Dis. 5:173-92
43. Girardi G, Yarilin D, Thurman JM, et al. 2006. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203:2165-75
44. Lynch AM, Murphy JR, Byers T, et al. 2008. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 198:385e1-9
45. Lynch AM, Salmon JE. 2010. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 31:561-67
46. Rampersad R, Barton A, Sadovsky Y, et al. 2008. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 29:855-61
47. Caprioli J, Noris M, Brioschi S, et al. 2006. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267-79
48. Fakhouri F, Jablonski M, Lepercq J, et al. 2008. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112:4542-45
49. Fang CJ, Richards A, Liszewski MK, et al. 2008. Advances in understanding of pathogenesis of aHUS and HELLP. Br. J. Haematol. 143:336-48
50. Lynch AM, Gibbs RS, Murphy JR, et al. 2011. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet. Gynecol. 117:75-83
51. Salmon JE, Heuser C, Triebwasser M, et al. 2011. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 8:e1001013
52. Thurman JM, Ljubanovic D, Royer PA, et al. 2006. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J. Clin. Invest. 116:357-68
53. Renner B, FerreiraVP, Cortes C, et al. 2011. Binding of factorHto tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 80:165-73
54. De Vries B, Matthijsen RA, Wolfs TG, et al. 2003. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 75:375-82
55. Ioannou A, Dalle Lucca J, Tsokos GC. 2011. Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clin. Immunol. 141:3-14
56. Stein JH, Osgood RW, Barnes JL, et al. 1985. The role of complement in the pathogenesis of postischemic acute renal failure. Miner. Electrolyte Metab. 11:256-61
57. Thurman JM. 2007. Triggers of inflammation after renal ischemia/reperfusion. Clin. Immunol. 123:7-13
58. Zhou W, Farrar CA, Abe K, et al. 2000. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 105:1363-71